Education
About Us
Working with TipRanks
Follow Us
Evgen Pharma PLC (GB:TCF)
LSE:TCF
TCF Stock Chart & Stats
0.20p
0.00p(0.00%)
At close: 4:00 PM EST
0.20p
0.00p(0.00%)
Day’s Range― - ―
52-Week Range0.18p - 0.30p
Previous CloseN/A
Volume87.69K
Average Volume (3M)1.69M
Market Cap
£4.94M
Enterprise Value3.38M
Total Cash (Recent Filing)£3.50M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Jun 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,148,963,600
10 Day Avg. Volume2,190,584
30 Day Avg. Volume1,685,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA lack of reported debt materially reduces fixed financing costs and insolvency risk, giving management structural flexibility to fund R&D or pursue partnerships without immediate interest burdens. This durable financial strength supports runway management and lowers leverage-related downside over months.
SFX Platform & Lead Clinical AssetA platform-led model with a clinical-stage lead (SFX-01) creates durable strategic optionality: the SFX platform can support multiple programs and indications, enhancing partnership/licensing attractiveness and potential milestone-based funding rather than relying solely on a single product launch.
Improving Cash Burn TrendSequential improvement in cash burn and narrowing losses signals better cost control or program prioritisation. While still cash-negative, a sustainable downward trend in burn can extend runway, reduce near-term financing pressure and improve ability to execute clinical milestones over the next several months.
Bears Say
Persistent Operating LossesOngoing structural losses erode equity and constrain reinvestment capacity; absent commercial revenue, persistent negative EBIT/EBITDA forces reliance on external capital and increases execution risk for clinical programs, making multi-quarter continuity dependent on financing or partners.
Weak Cash GenerationConsistently negative operating and free cash flow means the business cannot self-fund R&D or operations. This persistent cash shortfall increases vulnerability to market conditions when raising capital and can delay programs or force unfavorable licensing terms, a structural funding risk.
Inconsistent Or Minimal RevenueMinimal and inconsistent revenue—including zero-revenue periods—means there is no reliable commercial cash inflow to support operations. This undermines long-term profitability prospects and makes strategic planning dependent on uncertain milestone payments or capital raises.
Evgen Pharma News
TCF FAQ
What was Evgen Pharma PLC’s price range in the past 12 months?
Evgen Pharma PLC lowest share price was 0.17p and its highest was 0.30p in the past 12 months.
What is Evgen Pharma PLC’s market cap?
Evgen Pharma PLC’s market cap is £4.94M.
When is Evgen Pharma PLC’s upcoming earnings report date?
Evgen Pharma PLC’s upcoming earnings report date is Jun 10, 2026 which is in 107 days.
How were Evgen Pharma PLC’s earnings last quarter?
Evgen Pharma PLC released its earnings results on Dec 03, 2025. The company reported -0.001p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001p.
Is Evgen Pharma PLC overvalued?
According to Wall Street analysts Evgen Pharma PLC’s price is currently Overvalued.
Does Evgen Pharma PLC pay dividends?
Evgen Pharma PLC does not currently pay dividends.
What is Evgen Pharma PLC’s EPS estimate?
Evgen Pharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evgen Pharma PLC have?
Evgen Pharma PLC has 2,148,963,600 shares outstanding.
What happened to Evgen Pharma PLC’s price movement after its last earnings report?
Evgen Pharma PLC reported an EPS of -0.001p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.526%.
Which hedge fund is a major shareholder of Evgen Pharma PLC?
Currently, no hedge funds are holding shares in GB:TCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evgen Pharma PLC
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
ValiRx plc
―
Options Prices
Currently, No data available
---